REMARKS

Claims 1-4, 6-10, and 12-35 are all the claims pending in the application. Claim 11 has been indicated as being allowable. Claim 11 has been cancelled above; and claims 1, 20, 23-25, 27 and 30 have been rewritten to incorporate the limitations of claim 11 to place the claims in the application in condition for immediate allowance. Dependent claims 12-15 have been amended to now depend from independent claim 1, and should therefore be allowed.

Applicants have amended claims 1, 12-15, 20, 22-25, 27, and 30 and cancelled claim 11 from further consideration in this application. Applicants are not conceding in this application that those claims are not patentable over the art cited by the Examiner, as the present claim amendments and cancellations are only for facilitating expeditious prosecution of the allowable subject matter noted by the Examiner. Applicants respectfully reserve the right to pursue these and other claims in one or more continuations and/or divisional patent applications.

In view of the foregoing, Applicants submit that claims 1-4, 6-10, and 12-35, all the claims presently pending in the application, are patentably distinct from the prior art of record and are in condition for allowance. The Examiner is respectfully requested to pass the above application to issue at the earliest possible time.

Pursuant to new Rule 37 CFR 1.75(b) and *Pfizer Inc. v. Ranbaxy Labs, Ltd.*, 437 F.3d 1284, 1292, 70 U.S.P.Q.2d 1583, 1589-90 (Fed. Cir. 2006) all the dependent claims have been amended above to incorporate the claim language as specified in the new rule. Specifically, 37 CFR 1.75(b) states "a dependent claim must contain a reference to a claim previously set forth in the same application, incorporate by reference all the limitations of the previous claim to which such dependent claim refers, and specify a further limitation of the subject matter of the previous claim."

Should the Examiner find the application to be other than in condition for allowance, the Examiner is requested to contact the undersigned at the local telephone number listed below to discuss any other changes deemed necessary.

Please charge any deficiencies and credit any overpayments to Attorney's Deposit Account Number 09-0441.

Respectfully submitted,

Dated: January 10, 2008 /Frederick W. Gibb, III/

Frederick W. Gibb, III Registration No. 37,629

Gibb & Rahman, LLC 2568-A Riva Road, Suite 304 Annapolis, MD 21401 Voice: (410) 573-1545 Fax: (301) 261-8825

Customer Number: 29154